Latest news about Sat Kartar Life
Sat Kartar Life
181.00
-7.00(-3.72%)
Company Performance:
View Company Insights1D-3.72%
1M-10.53%
6M-0.77%
1Y-3.75%
5Y+12.04%
More news about Sat Kartar Life
07May 26
Sat Kartar Life Limited Receives NSE No-Objection for Reclassification of SK Sarthi Private Limited from Promoter Group to Public Category
Sat Kartar Life Limited (formerly known as Sat Kartar Shopping Limited) has received a no-objection letter from NSE vide Ref. No. NSE/LIST/COMP/SATKARTAR/554/2026-27, dated May 06, 2026, for reclassifying SK Sarthi Private Limited from the 'Promoter Group' to the 'Public' category under Regulation 31A of SEBI LODR Regulations, 2015. The application for reclassification was originally submitted on January 28, 2026. Since SK Sarthi Private Limited holds less than 1% of the company's paid-up share capital, shareholder approval is not required for this reclassification.
07May 26
Sat Kartar Life FY26 PAT Surges 74.31% to ₹17.10 Cr; Targets ₹500 Cr Revenue by FY28
Sat Kartar Life reported a 23.19% YoY increase in FY26 revenue to ₹200.70 Cr and a 74.31% surge in PAT to ₹17.10 Cr. EBITDA rose 73.51% to ₹24.69 Cr with margin expansion. The company announced strategic initiatives including a preferential issue of ₹48.58 Cr, a partnership with Jeena Sikho Lifecare, and the acquisition of Plantomed Neutraceuticals. Management targets ₹500 Cr revenue by FY28.
05May 26
Sat Kartar Life Limited Promoters Declare No Share Encumbrance for Financial Year Ended March 31, 2026
Sat Kartar Life Limited (formerly Sat Kartar Shopping Limited) has filed a declaration with NSE confirming that its promoters and persons acting in concert have not made any encumbrance on their shares for the financial year ended March 31, 2026. The declaration was submitted by promoter Manprit Singh Chadha on April 1, 2026, and forwarded to NSE by Company Secretary Sonal Seth on April 3, 2026. The filing is in accordance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Zydus Life Science
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,799.20
(-2.45%)
6,667.00
(-1.92%)
4,410.80
(-2.80%)
1,401.00
(-1.21%)
1,303.50
(-1.18%)
1,077.70
(-0.75%)
2,267.70
(-0.38%)
2,375.60
(-1.85%)
1,426.40
(-0.66%)
1,362.00
(-1.43%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
